OncoMark is an Irish DIAGNOSTICS company focused on the development of novel panels of cancer biomarkers to aid treatment decisions and allow more tailored patient management, ultimately improving the quality of life for cancer patients.
Our aim is to develop and commercialise a comprehensive portfolio of proprietary oncological assays that address unmet clinical needs and market gaps. OncoMark’s lead product, OncoMasTR is a novel prognostic test for early stage breast cancer. This gene expression profiling test accurately estimates the risk of recurrence for patients and thus aids the clinicians in identifying those that do not need to undergo chemotherapy and determining the best treatment options for their patients. The development of OncoMasTR utilised the OncoMasTR Technology, which identifies upstream drivers of cancer progression. This technology has the potential to be applied in other human cancers where significant unmet needs also exist.
OncoMark is involved in several EU Research projects (FP7 and Horizon 2020, Irish Research Council, Enterprise Ireland, Science Foundation Ireland and Marie Sklodowska-Curie Actions) covering the development of personalised medicine-orientated assays in melanoma, breast, prostate and colorectal cancers which have the potential to enter our product pipeline.
Our partners include universities, research institutes, clinical oncology groups, spin-outs and large biotech companies. Research funding has greatly aided our development from a spin-out entity into a rapidly expanding company with a growing staff of experienced international scientists.